<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67097</article-id><article-id pub-id-type="doi">10.7554/eLife.67097</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-224542"><name><surname>Rajasekaran</surname><given-names>Surender</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4430-006X</contrib-id><email>surender.rajasekaran@helendevoschildrens.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-226181"><name><surname>Bupp</surname><given-names>Caleb P</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-226182"><name><surname>Leimanis-Laurens</surname> <given-names>Mara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226183"><name><surname>Shukla</surname><given-names>Ankit</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226184"><name><surname>Russell</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226185"><name><surname>Junewick</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226186"><name><surname>Gleason</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226187"><name><surname>VanSickle</surname><given-names>Elizabeth A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5504-9248</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226188"><name><surname>Edgerly</surname><given-names>Yvonne</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226189"><name><surname>Wittmann</surname><given-names>Bryan M</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-226190"><name><surname>Prokop</surname><given-names>Jeremy W</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-226191"><name><surname>Bachmann</surname><given-names>André S</given-names></name><email>bachma26@msu.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Pediatric Critical Care Medicine, Helen DeVos Children’s Hospital</institution><addr-line><named-content content-type="city">Grand Rapids</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Spectrum Health Office of Research and Education</institution><addr-line><named-content content-type="city">Grand Rapids</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University</institution><addr-line><named-content content-type="city">Grand Rapids</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Medical Genetics, Spectrum Health and Helen DeVos Children’s Hospital</institution><addr-line><named-content content-type="city">Grand Rapids</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Pharmacy, Helen DeVos Children’s Hospital</institution><addr-line><named-content content-type="city">Grand Rapids</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Diagnostic Radiology, Spectrum Health and Helen DeVos Children's Hospital</institution><addr-line><named-content content-type="city">Grand Rapids</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Metabolon</institution><addr-line><named-content content-type="city">Morrisville</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University</institution><addr-line><named-content content-type="city">East Lansing</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Narla</surname><given-names>Goutham</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>20</day><month>07</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67097</elocation-id><history><date date-type="received" iso-8601-date="2021-01-31"><day>31</day><month>01</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-16"><day>16</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Rajasekaran et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Rajasekaran et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67097-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Polyamine levels are intricately controlled by biosynthetic, catabolic enzymes and antizymes. The complexity suggests that minute alterations in levels lead to profound abnormalities. We described the therapeutic course for a rare syndrome diagnosed by whole exome sequencing caused by gain-of-function variants in the C-terminus of ornithine decarboxylase (ODC), characterized by neurological deficits and alopecia.</p></sec><sec id="abs2"><title>Methods:</title><p><italic>N-</italic>acetylputrescine levels with other metabolites were measured using ultra-performance liquid chromatography paired with mass spectrometry and Z-scores established against a reference cohort of 866 children.</p></sec><sec id="abs3"><title>Results:</title><p>From previous studies and metabolic profiles, eflornithine was identified as potentially beneficial with therapy initiated on FDA approval. Eflornithine normalized polyamine levels without disrupting other pathways. She demonstrated remarkable improvement in both neurological symptoms and cortical architecture. She gained fine motor skills with the capacity to feed herself and sit with support.</p></sec><sec id="abs4"><title>Conclusions:</title><p>This work highlights the strategy of repurposing drugs to treat a rare disease.</p></sec><sec id="abs5"><title>Funding:</title><p>No external funding was received for this work.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>whole exome sequencing</kwd><kwd>repurposing drugs</kwd><kwd>global metabolomics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic sequencing has led to the increased diagnoses of rare diseases, strategies such as repurposing drugs and global metabolomics offer promise and bring hope to afflicted families.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Ornithine decarboxylase (ODC) is a rate-limiting enzyme in the biosynthesis of polyamines (putrescine, spermidine, spermine), which orchestrate essential physiological and pathologic processes including embryogenesis, organogenesis, and neoplastic cell growth (<xref ref-type="bibr" rid="bib3">Bello-Fernandez et al., 1993</xref>; <xref ref-type="bibr" rid="bib10">Pendeville et al., 2001</xref>). We recently described a new autosomal dominant genetic disorder (Bachmann-Bupp syndrome, OMIM #619075) caused by a heterozygous de novo variant in the <italic>ODC1</italic> gene in a 3-year-old girl with phenotypic features that included alopecia universalis and global developmental delay (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib4">Bupp et al., 2018</xref>). The nonsense variant caused premature abrogation of 14-aa residues in the C-terminus of the protein (ODC, p·K448X, <xref ref-type="fig" rid="fig2">Figure 2</xref>), leading to enhanced function. Red blood cells from the patient exhibited elevated ODC activity and putrescine levels compared to healthy controls. Four additional patients with similar mutations and phenotypic features of this syndrome have since been reported (<xref ref-type="bibr" rid="bib12">Rodan et al., 2018</xref>) and at least four more cases have been identified.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Patient phenotypes and metabolites before and after eflornithine treatment.</title><p>Panel <bold>A</bold> shows the timeline of events for the patient with milestones marked on the top and clinical observations below. Panels <bold>B-C</bold> show hair growth and muscle tone are the most noticeable phenotype changes with treatment. Follicular cysts recurred on back, neck, and posterior scalp (bottom left images). First hair growth was eyebrows 1 month into treatment (bottom right images). Panel <bold>D</bold> shows MRI before and after eflornithine treatment. Neonatal: Axial T1 (TR 483 ms, TE 9 ms, and flip angle 63 degrees), T2 (TR 3250 ms, TE 220 ms, and flip angle 90 degrees), and T2-FLAIR (TR 8002 ms, TE 122 ms, and flip angle 90 degrees) show marked abnormal signal of cerebral white matter (*) and several subependymal cysts (arrows). Five years of age: Axial T1 (TR 809 ms, TE 16 ms, and flip angle 111 degrees), T2 (TR 4850 ms, TE 107 ms, and flip angle 142 degrees), and T2-FLAIR (TR 6002 ms, TE 91 ms, and flip angle 90 degrees) show decrease in cerebral white matter volume, but normalization of signal and resolution of subependymal cysts.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67097-fig1-v1.tif"/></fig><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>ODC1/ODC clinical variant c.1342 A &gt; T/ p.K448X</italic> and support for eflornithine treatment.</title><p>Panel <bold>A</bold> shows the gene structure for ODC1 (ornithine decarboxylase 1) with active site amino acids labeled in blue and the last exon identified. In the last exon cluster, a mouse model variant and four different patient variants including our patient’s K448X variant are described (Panel <bold>B</bold>, red). The patient variant falls on the disordered C-terminus of ODC, where the two active sites are composed of amino acids from each of two ODC proteins forming a dimer (Panel <bold>C</bold>). The patient with K448X variant displays alterations of metabolic pathways (Panel <bold>D</bold>) including polyamines (triangle), urea (square), and others (circle). Metabolites measured are marked in cyan and those altered by K448X with red arrows based on direction of changes seen in the patient. Panel E shows changes in metabolite levels during treatment with eflornithine, with elevated levels of N-acetylputrescine and acisoga decreasing on therapy.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67097-fig2-v1.tif"/></fig><p>Remarkably, these patients all represent human phenotypes of a transgenic mouse described in 1996, overexpressing C-terminally deleted ODC in the dermal tissue, leading to higher ODC enzyme activity and increased putrescine biosynthesis (<xref ref-type="bibr" rid="bib15">Soler et al., 1996</xref>). The phenotypic changes first described in a mouse model included hair loss that was reversible with ODC inhibitor α-difluoromethylornithine (DFMO; common name eflornithine) (<xref ref-type="bibr" rid="bib15">Soler et al., 1996</xref>). Experiments with the patient’s cultured primary dermal fibroblasts showed eflornithine reduced ODC activity, resulting in putrescine levels comparable to controls without affecting cell morphology or inducing cell death (<xref ref-type="bibr" rid="bib14">Schultz et al., 2019</xref>).</p><p>Based on previously published murine data with eflornithine for gain-of-function variants (<xref ref-type="bibr" rid="bib15">Soler et al., 1996</xref>), multiple long-term safety studies for clinical use in African sleeping sickness (trypanosomiasis), colorectal cancer, and neuroblastoma (<xref ref-type="bibr" rid="bib1">Alirol et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Priotto et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Saulnier Sholler et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Meyskens et al., 2008</xref>), and the absense of toxicity in the patient’s primary cell culture inresponse to eflornithine (<xref ref-type="bibr" rid="bib14">Schultz et al., 2019</xref>), we surmised eflornithine might be a novel therapy for patients with this syndrome.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Gene (<italic>Homo sapiens</italic>)</td><td valign="top"><italic>ODC1</italic></td><td valign="top">NCBI Gene</td><td valign="top">Gene ID: 4953</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene/4953">https://www.ncbi.nlm.nih.gov/gene/4953</ext-link></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top"><italic>Eflornithine</italic> (<italic>DFMO</italic>)</td><td valign="top">Sanofi Aventis</td><td valign="top"> Supplied for study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Eflornithine">https://pubchem.ncbi.nlm.nih.gov/compound/Eflornithine</ext-link></td></tr><tr><td valign="top">Biological sample (<italic>Homo sapiens</italic>)</td><td valign="top">Blood EDTA tubes</td><td valign="top"/><td valign="top"/><td valign="top">Freshly isolated blood from patient</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">YASARA</td><td valign="top">YASARA</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.yasara.org/">http://www.yasara.org/</ext-link></td><td valign="top">Protein modelling</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top"><italic>Liquid chromatography paired massspectrometry</italic></td><td valign="top">Metabolon, Morrisville, NC</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.metabolon.com/">https://www.metabolon.com/</ext-link></td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s2-1"><title>Study participants and consent </title><p>Following FDA approval of our single-patient Investigational New Drug (IND) Application (144022) as a compassionate use treatment protocol, the study was further reviewed and approved by the Spectrum Health Institutional Review Board (IRB). IRB approval for sample collection with informed consent was received to conduct global metabolomics that included, among others, the polyamine metabolites spermidine and <italic>N</italic>-acetylputrescine.</p><p>The patient first presented at Spectrum Health, Helen DeVos Children’s Hospital (Grand Rapids, MI) at 11 months of age (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We diagnosed the ODC C-terminal deletion at age 19 months through whole exome sequencing and characterized the metabolic dyshomeostasis by 32 months (ODC protein and polyamine abnormalities). Eflornithine oral solution was prepared by diluting the lyophilized powder with purified water to a final concentration of 100 mg/mL. At age 4 years and 8 months, we started eflornithine (Sanofi Aventis) treatment with 500 mg/m<sup>2</sup>/dose bid twice daily via a gastrostomy tube along with a low polyamine diet on November 14, 2019, for 3 months, increasing to 750 mg/m<sup>2</sup>/dose twice daily, and a final increase to 1000 mg/m<sup>2</sup>/dose twice daily after 3.5 months. Dosing was based on what had been demonstrated to be safe in pediatric patients in maintenance therapy for neuroblastoma treated with eflornithine (<xref ref-type="bibr" rid="bib13">Saulnier Sholler et al., 2015</xref>).</p></sec><sec id="s2-2"><title>Blood collection and processing</title><p>EDTA blood tubes collected from the patient were mixed by inversion 8–10 times, centrifuged at 1000×<italic>g</italic> for 10 min at 4°C to separate plasma (minimum of 0.25 mL, free of hemolysis from red blood cells) from cellular fraction, and both fractions were immediately placed at −80°C. The plasma specimens were coded and anonymized, kept frozen, and shipped in batch to Metabolon, Morrisville, NC, for metabolomics analysis. <italic>N</italic>-acetylputrescine, the only polyamine that meets CAP/CLIA standards in this analysis, served as the primary indicator of putrescine levels. <italic>N</italic>-acetylputrescine and additional metabolites meeting CAP/CLIA standards (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and supplemental metabolites were measured in the EDTA plasma samples using ultra-performance liquid chromatography paired with mass spectrometry and Z-scores were calculated for each metabolite against a reference cohort of 866 pediatric patients as described previously (<xref ref-type="bibr" rid="bib17">Squitti et al., 2019</xref>).</p><p>Blood draws for polyamine levels were obtained at initiation of therapy, 1-week post-initiation, immediately prior to each dose increase and then 7 days after each dose increase. These draws were performed in conjunction with safety screening, which included a complete blood count, liver function test, lactate dehydrogenase, complete metabolic panel, calcium, magnesium, and phosphate.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>The novel treatment of this ultra-rare (less than 10 known cases) genetic syndrome presented unique challenges for monitoring efficacy over time. Growth parameters and metabolite levels were monitored easily, whereas others such as cognitive and motor functioning proved challenging, making us dependent on her standardized neurological examination.</p><sec id="s3-1"><title>Eflornithine improves clinical findings</title><p>The patient was born with a full head of silver-blond hair similar to a previously described murine phenotype (<xref ref-type="bibr" rid="bib15">Soler et al., 1996</xref>), which fell out in early months and she remained hairless other than a few scattered, long hairs on the scalp. One month into treatment, hair growth was noted, with eyebrows appearing first (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). Two months into treatment, scalp hair began to diffusely appear in the normal pattern of hair distribution increasing to resemble normal growth for age (<xref ref-type="fig" rid="fig1">Figure 1</xref>). She had a history of recurring follicular cyst formation and enlargement. Multiple lesions located on the posterior scalp and back that first were small maculopapular pustules slowly increased in size to approximately 6–7 cm in diameter (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These lysed spontaneously, but some would enlarge until painful, requiring surgical removal. Upon initiation of eflornithine, the formation of cysts ceased immediately (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>Prior to therapy, she had delayed development which manifested with no standing, cruising, or sitting, and limited fine motor skills. Her BMI increased during eflornithine treatment from 25th percentile to 90th percentile primarily due to increase in weight. This quantitative change was not accompanied by any change in body habitus but rather an increase in muscle bulk. She gained muscle strength demonstrated by acquisition of her ability to hold up her head without support (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). As the video file shows after 4 months of eflornithine therapy, she was able to sit unsupported and maintain posture with the physical therapist providing resistance, use a walker, and feed herself with a spoon with some assistance. <xref ref-type="video" rid="video1">Video 1</xref> allows for optimal visualization of this rapid improvement of our patient with this gain-of-function mutation in the <italic>ODC1</italic> gene. The drastic external change in hair growth, and visible improvement in coordination, attention, and interaction can be clearly seen.</p><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-67097-video1.mp4"><label>Video 1.</label><caption><title>Treatment progression after 4 months of eflornithine therapy.</title></caption></media><p>A neonatal brain MRI showed abnormal cerebral white matter and subependymal cysts (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Repeat MRI done at the end of the 9-month treatment trial with eflornithine demonstrated normalization of the cerebral white matter signal with decrease in volume with white matter loss and resolution of all previously noted cysts. Post-treatment magnetic resonance spectroscopy was also performed showing normalization of the <italic>N</italic>-acetylaspartate and choline signals relative to creatine <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</p></sec><sec id="s3-2"><title>Eflornithine normalizes metabolomic findings</title><p><italic>N</italic>-acetylputrescine, the only polyamine metabolite measurement that is CAP/CLIA-certified, was quantified in addition to others using a global metabolomics approach (<xref ref-type="fig" rid="fig2">Figure 2</xref>) before and after initiating therapy with eflornithine. Metabolite levels from a reference cohort of 866 pediatric patients were converted into Z-scores, a calculation of standard deviations from the mean of the reference populationthat our patient’s values are compared to. In the global analysis of 915 metabolites of the patient before treatment, a total of 16 had values above the 97.5th percentile and 38 below the 2.5th percentile, with a noted difference in polyamine connected metabolites (<xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>) without any marked disruption of any other metabolic pathways on treatment. The initial elevation of both <italic>N</italic>-acetylputrescine as well as the polyamine metabolite <italic>N</italic>-(3-acetamidopropyl) pyrrolidin-2-one (acisoga), which were above the 97.5th percentile, decreased at initiation of therapy and remained reduced at all time points (<xref ref-type="fig" rid="fig2">Figure 2</xref>), indicating that eflornithine treatment had the expected effect. Ornithine and <italic>N</italic>-acetylarginine were below the 2.5th percentile at start of therapy and normalized to the larger pediatric values over the course of therapy. Urea cycle components citrulline and arginine, along with other metabolites, remained at 1 to −1 standard deviation throughout the study period (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>The introduction of both whole genome and exome sequencing into clinical practice has led to rare diseases being diagnosed at rates never before seen (<xref ref-type="bibr" rid="bib19">Turro et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Tarailo-Graovac et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Splinter et al., 2018</xref>). There are over 6000 rare diseases (incidence of greater than 1 in 2000 people) with over 300 million people worldwide affected (<xref ref-type="bibr" rid="bib9">Nguengang Wakap et al., 2020</xref>). Though collectively common, each rare disease is unique making it challenging to develop specific therapies.</p><p>The process of developing treatment options for these rare diseases starts with a description of the genetic abnormality and developing an understanding of the molecular disruptions downstream from the affected protein. Once the biochemical perturbations are identified, then the quest to identify a drug that will return molecular pathways to normal begins. In genetic diseases, the correct mechanism to adopt could be challenging as many options exist such as activating or repressing pathways, enzyme blockade therapy, gene therapy regimens (<xref ref-type="bibr" rid="bib7">Mendell et al., 2017</xref>), and potentially circumventing or correcting a genetic mutation such as treatments for muscular dystrophy (<xref ref-type="bibr" rid="bib6">Iyer et al., 2019</xref>). Taking a genetic defect to human trials requires cell cultures, animal studies, and phased trials to determine safety and efficacy of such therapies. For multiple patients, often with unique genetic variants, to see benefit from this process could take the best part of a decade even as identification of successful drugs has been enhanced by the Orphan Drug Act (<xref ref-type="bibr" rid="bib2">Augustine et al., 2013</xref>; <xref ref-type="bibr" rid="bib5">Griggs et al., 2009</xref>).</p><p>We show a more rapid strategy of matching a patient with an ultra-rare newly identified syndrome to a drug with subsequent treatment being able to safely correct many phenotypic features. Once the whole exome identified the biochemical pathway, we used data from a previously described transgenic mouse model and our published cell culture study to surmise, eflornithine therapy could be of benefit to the patient. Though experimental data suggested that eflornithine could be beneficial, there is a chasm between ex vivo and in vivo studies with difficulties in extrapolating efficacy or safety from a fibroblast study alone (<xref ref-type="bibr" rid="bib14">Schultz et al., 2019</xref>). We were fortunate that studies existed for eflornithine in a large enough population to suggest dosage and safety (<xref ref-type="bibr" rid="bib1">Alirol et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Priotto et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Saulnier Sholler et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Meyskens et al., 2008</xref>).</p><p>Once therapy was initiated, some neurological improvement in the patient was noted with better posture, weight gain, reduction, elimination of cyst formation, and significant hair growth. Six months into therapy, she had fine motor capability that she previously lacked, such as the capacity to feed herself and sit with some support. Brain imaging also showed changes that are beyond what would be explained merely by the passage of time, suggesting improvement related to eflornithine treatment.</p><p>While COVID-19 restrictions interrupted neurological assessments over the treatment period, the improvements noted throughout the relatively short treatment period of 6 months are truly remarkable, especially given the neurological deterioration in the patient prior to eflornithine therapy. This could be especially consequential if we could initiate therapy in a neonate diagnosed early before neurological damage occurs. We are now aware of other patients identified that present with similar gain-of-function ODC variants and polyamine abnormalities such as elevated <italic>N</italic>-acetylputrescine (<xref ref-type="bibr" rid="bib12">Rodan et al., 2018</xref>). The therapy outlined here should allow for replication of the findings with a promise for significant improvement in quality of life for these patients. For such patients we recommend continued monitoring of multiple metabolites including <italic>N</italic>-acetylputrescine and acisoga to ensure that eflornithine dosing and urea/polyamine metabolite levels stay within normal ranges. The advent of global metabolomics presents a unique opportunity not only to develop a complete understanding of the dyshomeostasis prior to therapy but also a way to appreciate the drug’s impact on interconnected metabolic cycles simultaneously and perhaps a means of identifying disruptions early and predicting adverse effects. This may lead to earlier initiation of therapy in future patients, thereby perhaps avoiding some of the neurological delay that has come to characterize the disease in our patient.</p><sec id="s4-1"><title>Conclusion</title><p>In this study we have laid forth a promising example of going from first publication of a new syndrome to FDA-approved single-patient investigational repurposed drug treatment in 16 months, a methodology and speed rarely seen in the clinical science of rare diseases.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors wish to thank the patient and family for their participation. We would like to dedicate this article to our patient who is a first in so many ways, and to her incredible family. We acknowledge the support we received from the research team at Spectrum Health. We are most grateful to Sanofi-Aventis for providing eflornithine for this study. We also thank Dr B Keith English, MD, Charles Schwartz, PhD, and Brittany Essenmacher for the critical review and editing of this manuscript, David Tack, PhD, for the design of some of the figures, and Olivia Verburg for her help with processing samples and logging samples.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Inventor on a pending US patent (US-2020215010-A1), methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.</p></fn><fn fn-type="COI-statement" id="conf2"><p>Inventor on a pending US patent (US-2020215010-A1), methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf4"><p>Inventor on a pending US patent (US-2020215010-A1), methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Project administration</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con6"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Supervision</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con11"><p>Data curation, Investigation, Visualization</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: FDA approval (IND# 144022) was first acquired before therapy was initiated. The Spectrum Health IRB approved the study (IRB# 2019-161) and informed consent was acquired before blood sample collection. Consent was obtained for use of identifying patient images and videos within this manuscript. After study, authorization for publication was obtained from the parents of the child, now been placed in the medical records.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Global Metabolomics.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67097-data1-v1.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-67097-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data is provided in Source data 1.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alirol</surname> <given-names>E</given-names></name><name><surname>Schrumpf</surname> <given-names>D</given-names></name><name><surname>Amici Heradi</surname> <given-names>J</given-names></name><name><surname>Riedel</surname> <given-names>A</given-names></name><name><surname>de Patoul</surname> <given-names>C</given-names></name><name><surname>Quere</surname> <given-names>M</given-names></name><name><surname>Chappuis</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo</article-title><source>Clinical Infectious Diseases</source><volume>56</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1093/cid/cis886</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustine</surname> <given-names>EF</given-names></name><name><surname>Adams</surname> <given-names>HR</given-names></name><name><surname>Mink</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Clinical trials in rare disease: challenges and opportunities</article-title><source>Journal of Child Neurology</source><volume>28</volume><fpage>1142</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1177/0883073813495959</pub-id><pub-id pub-id-type="pmid">24014509</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bello-Fernandez</surname> <given-names>C</given-names></name><name><surname>Packham</surname> <given-names>G</given-names></name><name><surname>Cleveland</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The ornithine decarboxylase gene is a transcriptional target of c-Myc</article-title><source>PNAS</source><volume>90</volume><fpage>7804</fpage><lpage>7808</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.16.7804</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bupp</surname> <given-names>CP</given-names></name><name><surname>Schultz</surname> <given-names>CR</given-names></name><name><surname>Uhl</surname> <given-names>KL</given-names></name><name><surname>Rajasekaran</surname> <given-names>S</given-names></name><name><surname>Bachmann</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Novel de novo pathogenic variant in the <italic>ODC1</italic> gene in a girl with developmental delay, alopecia, and dysmorphic features</article-title><source>American Journal of Medical Genetics Part A</source><volume>176</volume><fpage>2548</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.40523</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griggs</surname> <given-names>RC</given-names></name><name><surname>Batshaw</surname> <given-names>M</given-names></name><name><surname>Dunkle</surname> <given-names>M</given-names></name><name><surname>Gopal-Srivastava</surname> <given-names>R</given-names></name><name><surname>Kaye</surname> <given-names>E</given-names></name><name><surname>Krischer</surname> <given-names>J</given-names></name><name><surname>Nguyen</surname> <given-names>T</given-names></name><name><surname>Paulus</surname> <given-names>K</given-names></name><name><surname>Merkel</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Clinical research for rare disease: Opportunities, challenges, and solutions</article-title><source>Molecular Genetics and Metabolism</source><volume>96</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2008.10.003</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname> <given-names>S</given-names></name><name><surname>Suresh</surname> <given-names>S</given-names></name><name><surname>Guo</surname> <given-names>D</given-names></name><name><surname>Daman</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>JCJ</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Zieger</surname> <given-names>M</given-names></name><name><surname>Luk</surname> <given-names>K</given-names></name><name><surname>Roscoe</surname> <given-names>BP</given-names></name><name><surname>Mueller</surname> <given-names>C</given-names></name><name><surname>King</surname> <given-names>OD</given-names></name><name><surname>Emerson</surname> <given-names>CP</given-names></name><name><surname>Wolfe</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Precise therapeutic gene correction by a simple nuclease-induced double-stranded break</article-title><source>Nature</source><volume>568</volume><fpage>561</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1076-8</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendell</surname> <given-names>JR</given-names></name><name><surname>Al-Zaidy</surname> <given-names>S</given-names></name><name><surname>Shell</surname> <given-names>R</given-names></name><name><surname>Arnold</surname> <given-names>WD</given-names></name><name><surname>Rodino-Klapac</surname> <given-names>LR</given-names></name><name><surname>Prior</surname> <given-names>TW</given-names></name><name><surname>Lowes</surname> <given-names>L</given-names></name><name><surname>Alfano</surname> <given-names>L</given-names></name><name><surname>Berry</surname> <given-names>K</given-names></name><name><surname>Church</surname> <given-names>K</given-names></name><name><surname>Kissel</surname> <given-names>JT</given-names></name><name><surname>Nagendran</surname> <given-names>S</given-names></name><name><surname>L’Italien</surname> <given-names>J</given-names></name><name><surname>Sproule</surname> <given-names>DM</given-names></name><name><surname>Wells</surname> <given-names>C</given-names></name><name><surname>Cardenas</surname> <given-names>JA</given-names></name><name><surname>Heitzer</surname> <given-names>MD</given-names></name><name><surname>Kaspar</surname> <given-names>A</given-names></name><name><surname>Corcoran</surname> <given-names>S</given-names></name><name><surname>Braun</surname> <given-names>L</given-names></name><name><surname>Likhite</surname> <given-names>S</given-names></name><name><surname>Miranda</surname> <given-names>C</given-names></name><name><surname>Meyer</surname> <given-names>K</given-names></name><name><surname>Foust</surname> <given-names>KD</given-names></name><name><surname>Burghes</surname> <given-names>AHM</given-names></name><name><surname>Kaspar</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy</article-title><source>New England Journal of Medicine</source><volume>377</volume><fpage>1713</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1706198</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyskens</surname> <given-names>FL</given-names></name><name><surname>McLaren</surname> <given-names>CE</given-names></name><name><surname>Pelot</surname> <given-names>D</given-names></name><name><surname>Fujikawa-Brooks</surname> <given-names>S</given-names></name><name><surname>Carpenter</surname> <given-names>PM</given-names></name><name><surname>Hawk</surname> <given-names>E</given-names></name><name><surname>Kelloff</surname> <given-names>G</given-names></name><name><surname>Lawson</surname> <given-names>MJ</given-names></name><name><surname>Kidao</surname> <given-names>J</given-names></name><name><surname>McCracken</surname> <given-names>J</given-names></name><name><surname>Albers</surname> <given-names>CG</given-names></name><name><surname>Ahnen</surname> <given-names>DJ</given-names></name><name><surname>Turgeon</surname> <given-names>DK</given-names></name><name><surname>Goldschmid</surname> <given-names>S</given-names></name><name><surname>Lance</surname> <given-names>P</given-names></name><name><surname>Hagedorn</surname> <given-names>CH</given-names></name><name><surname>Gillen</surname> <given-names>DL</given-names></name><name><surname>Gerner</surname> <given-names>EW</given-names></name><name><surname>Jr, McLaren</surname> <given-names>FL</given-names></name><name><surname>Pelot</surname> <given-names>CE</given-names></name><name><surname>Hawk</surname> <given-names>PM</given-names></name><name><surname>Lawson</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial</article-title><source>Cancer Prevention Research</source><volume>1</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-08-0042</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguengang Wakap</surname> <given-names>S</given-names></name><name><surname>Lambert</surname> <given-names>DM</given-names></name><name><surname>Olry</surname> <given-names>A</given-names></name><name><surname>Rodwell</surname> <given-names>C</given-names></name><name><surname>Gueydan</surname> <given-names>C</given-names></name><name><surname>Lanneau</surname> <given-names>V</given-names></name><name><surname>Murphy</surname> <given-names>D</given-names></name><name><surname>Le Cam</surname> <given-names>Y</given-names></name><name><surname>Rath</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database</article-title><source>European Journal of Human Genetics</source><volume>28</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/s41431-019-0508-0</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pendeville</surname> <given-names>H</given-names></name><name><surname>Carpino</surname> <given-names>N</given-names></name><name><surname>Marine</surname> <given-names>JC</given-names></name><name><surname>Takahashi</surname> <given-names>Y</given-names></name><name><surname>Muller</surname> <given-names>M</given-names></name><name><surname>Martial</surname> <given-names>JA</given-names></name><name><surname>Cleveland</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The ornithine decarboxylase gene is essential for cell survival during early murine development</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>6549</fpage><lpage>6558</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.19.6549-6558.2001</pub-id><pub-id pub-id-type="pmid">11533243</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priotto</surname> <given-names>G</given-names></name><name><surname>Kasparian</surname> <given-names>S</given-names></name><name><surname>Mutombo</surname> <given-names>W</given-names></name><name><surname>Ngouama</surname> <given-names>D</given-names></name><name><surname>Ghorashian</surname> <given-names>S</given-names></name><name><surname>Arnold</surname> <given-names>U</given-names></name><name><surname>Ghabri</surname> <given-names>S</given-names></name><name><surname>Baudin</surname> <given-names>E</given-names></name><name><surname>Buard</surname> <given-names>V</given-names></name><name><surname>Kazadi-Kyanza</surname> <given-names>S</given-names></name><name><surname>Ilunga</surname> <given-names>M</given-names></name><name><surname>Mutangala</surname> <given-names>W</given-names></name><name><surname>Pohlig</surname> <given-names>G</given-names></name><name><surname>Schmid</surname> <given-names>C</given-names></name><name><surname>Karunakara</surname> <given-names>U</given-names></name><name><surname>Torreele</surname> <given-names>E</given-names></name><name><surname>Kande</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nifurtimox-eflornithine combination therapy for second-stage African <italic>Trypanosoma brucei</italic> gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial</article-title><source>The Lancet</source><volume>374</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61117-X</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodan</surname> <given-names>LH</given-names></name><name><surname>Anyane-Yeboa</surname> <given-names>K</given-names></name><name><surname>Chong</surname> <given-names>K</given-names></name><name><surname>Klein Wassink-Ruiter</surname> <given-names>JS</given-names></name><name><surname>Wilson</surname> <given-names>A</given-names></name><name><surname>Smith</surname> <given-names>L</given-names></name><name><surname>Kothare</surname> <given-names>SV</given-names></name><name><surname>Rajabi</surname> <given-names>F</given-names></name><name><surname>Blaser</surname> <given-names>S</given-names></name><name><surname>Ni</surname> <given-names>M</given-names></name><name><surname>DeBerardinis</surname> <given-names>RJ</given-names></name><name><surname>Poduri</surname> <given-names>A</given-names></name><name><surname>Berry</surname> <given-names>GT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gain-of-function variants in the <italic>ODC1</italic> gene cause a syndromic neurodevelopmental disorder associated with macrocephaly, alopecia, dysmorphic features, and neuroimaging abnormalities</article-title><source>American Journal of Medical Genetics Part A</source><volume>176</volume><fpage>2554</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.60677</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saulnier Sholler</surname> <given-names>GL</given-names></name><name><surname>Gerner</surname> <given-names>EW</given-names></name><name><surname>Bergendahl</surname> <given-names>G</given-names></name><name><surname>MacArthur</surname> <given-names>RB</given-names></name><name><surname>VanderWerff</surname> <given-names>A</given-names></name><name><surname>Ashikaga</surname> <given-names>T</given-names></name><name><surname>Bond</surname> <given-names>JP</given-names></name><name><surname>Ferguson</surname> <given-names>W</given-names></name><name><surname>Roberts</surname> <given-names>W</given-names></name><name><surname>Wada</surname> <given-names>RK</given-names></name><name><surname>Eslin</surname> <given-names>D</given-names></name><name><surname>Kraveka</surname> <given-names>JM</given-names></name><name><surname>Kaplan</surname> <given-names>J</given-names></name><name><surname>Mitchell</surname> <given-names>D</given-names></name><name><surname>Parikh</surname> <given-names>NS</given-names></name><name><surname>Neville</surname> <given-names>K</given-names></name><name><surname>Sender</surname> <given-names>L</given-names></name><name><surname>Higgins</surname> <given-names>T</given-names></name><name><surname>Kawakita</surname> <given-names>M</given-names></name><name><surname>Hiramatsu</surname> <given-names>K</given-names></name><name><surname>Moriya</surname> <given-names>S-S</given-names></name><name><surname>Bachmann</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0127246</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0127246</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname> <given-names>CR</given-names></name><name><surname>Bupp</surname> <given-names>CP</given-names></name><name><surname>Rajasekaran</surname> <given-names>S</given-names></name><name><surname>Bachmann</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biochemical features of primary cells from a pediatric patient with a gain-of-function ODC1 genetic mutation</article-title><source>Biochemical Journal</source><volume>476</volume><fpage>2047</fpage><lpage>2057</lpage><pub-id pub-id-type="doi">10.1042/BCJ20190294</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soler</surname> <given-names>AP</given-names></name><name><surname>Gilliard</surname> <given-names>G</given-names></name><name><surname>Megosh</surname> <given-names>LC</given-names></name><name><surname>O'Brien</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Modulation of murine hair follicle function by alterations in ornithine decarboxylase activity</article-title><source>Journal of Investigative Dermatology</source><volume>106</volume><fpage>1108</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12340155</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Splinter</surname> <given-names>K</given-names></name><name><surname>Adams</surname> <given-names>DR</given-names></name><name><surname>Bacino</surname> <given-names>CA</given-names></name><name><surname>Bellen</surname> <given-names>HJ</given-names></name><name><surname>Bernstein</surname> <given-names>JA</given-names></name><name><surname>Cheatle-Jarvela</surname> <given-names>AM</given-names></name><name><surname>Eng</surname> <given-names>CM</given-names></name><name><surname>Esteves</surname> <given-names>C</given-names></name><name><surname>Gahl</surname> <given-names>WA</given-names></name><name><surname>Hamid</surname> <given-names>R</given-names></name><name><surname>Jacob</surname> <given-names>HJ</given-names></name><name><surname>Kikani</surname> <given-names>B</given-names></name><name><surname>Koeller</surname> <given-names>DM</given-names></name><name><surname>Kohane</surname> <given-names>IS</given-names></name><name><surname>Lee</surname> <given-names>BH</given-names></name><name><surname>Loscalzo</surname> <given-names>J</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>McCray</surname> <given-names>AT</given-names></name><name><surname>Metz</surname> <given-names>TO</given-names></name><name><surname>Mulvihill</surname> <given-names>JJ</given-names></name><name><surname>Nelson</surname> <given-names>SF</given-names></name><name><surname>Palmer</surname> <given-names>CGS</given-names></name><name><surname>Phillips</surname> <given-names>JA</given-names></name><name><surname>Pick</surname> <given-names>L</given-names></name><name><surname>Postlethwait</surname> <given-names>JH</given-names></name><name><surname>Reuter</surname> <given-names>C</given-names></name><name><surname>Shashi</surname> <given-names>V</given-names></name><name><surname>Sweetser</surname> <given-names>DA</given-names></name><name><surname>Tifft</surname> <given-names>CJ</given-names></name><name><surname>Walley</surname> <given-names>NM</given-names></name><name><surname>Wangler</surname> <given-names>MF</given-names></name><name><surname>Westerfield</surname> <given-names>M</given-names></name><name><surname>Wheeler</surname> <given-names>MT</given-names></name><name><surname>Wise</surname> <given-names>AL</given-names></name><name><surname>Worthey</surname> <given-names>EA</given-names></name><name><surname>Yamamoto</surname> <given-names>S</given-names></name><name><surname>Ashley</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effect of genetic diagnosis on patients with previously undiagnosed disease</article-title><source>New England Journal of Medicine</source><volume>379</volume><fpage>2131</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1714458</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squitti</surname> <given-names>R</given-names></name><name><surname>Cerchiaro</surname> <given-names>G</given-names></name><name><surname>Giovannoni</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A case of a mild wolfram syndrome with concomitant ATP7B mutation</article-title><source>CellR4</source><volume>7</volume><elocation-id>e2735</elocation-id><pub-id pub-id-type="doi">10.32113/cellr4_20198_2735</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarailo-Graovac</surname> <given-names>M</given-names></name><name><surname>Shyr</surname> <given-names>C</given-names></name><name><surname>Ross</surname> <given-names>CJ</given-names></name><name><surname>Horvath</surname> <given-names>GA</given-names></name><name><surname>Salvarinova</surname> <given-names>R</given-names></name><name><surname>Ye</surname> <given-names>XC</given-names></name><name><surname>Zhang</surname> <given-names>L-H</given-names></name><name><surname>Bhavsar</surname> <given-names>AP</given-names></name><name><surname>Lee</surname> <given-names>JJY</given-names></name><name><surname>Drögemöller</surname> <given-names>BI</given-names></name><name><surname>Abdelsayed</surname> <given-names>M</given-names></name><name><surname>Alfadhel</surname> <given-names>M</given-names></name><name><surname>Armstrong</surname> <given-names>L</given-names></name><name><surname>Baumgartner</surname> <given-names>MR</given-names></name><name><surname>Burda</surname> <given-names>P</given-names></name><name><surname>Connolly</surname> <given-names>MB</given-names></name><name><surname>Cameron</surname> <given-names>J</given-names></name><name><surname>Demos</surname> <given-names>M</given-names></name><name><surname>Dewan</surname> <given-names>T</given-names></name><name><surname>Dionne</surname> <given-names>J</given-names></name><name><surname>Evans</surname> <given-names>AM</given-names></name><name><surname>Friedman</surname> <given-names>JM</given-names></name><name><surname>Garber</surname> <given-names>I</given-names></name><name><surname>Lewis</surname> <given-names>S</given-names></name><name><surname>Ling</surname> <given-names>J</given-names></name><name><surname>Mandal</surname> <given-names>R</given-names></name><name><surname>Mattman</surname> <given-names>A</given-names></name><name><surname>McKinnon</surname> <given-names>M</given-names></name><name><surname>Michoulas</surname> <given-names>A</given-names></name><name><surname>Metzger</surname> <given-names>D</given-names></name><name><surname>Ogunbayo</surname> <given-names>OA</given-names></name><name><surname>Rakic</surname> <given-names>B</given-names></name><name><surname>Rozmus</surname> <given-names>J</given-names></name><name><surname>Ruben</surname> <given-names>P</given-names></name><name><surname>Sayson</surname> <given-names>B</given-names></name><name><surname>Santra</surname> <given-names>S</given-names></name><name><surname>Schultz</surname> <given-names>KR</given-names></name><name><surname>Selby</surname> <given-names>K</given-names></name><name><surname>Shekel</surname> <given-names>P</given-names></name><name><surname>Sirrs</surname> <given-names>S</given-names></name><name><surname>Skrypnyk</surname> <given-names>C</given-names></name><name><surname>Superti-Furga</surname> <given-names>A</given-names></name><name><surname>Turvey</surname> <given-names>SE</given-names></name><name><surname>Van Allen</surname> <given-names>MI</given-names></name><name><surname>Wishart</surname> <given-names>D</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Zafeiriou</surname> <given-names>D</given-names></name><name><surname>Kluijtmans</surname> <given-names>L</given-names></name><name><surname>Wevers</surname> <given-names>RA</given-names></name><name><surname>Eydoux</surname> <given-names>P</given-names></name><name><surname>Lehman</surname> <given-names>AM</given-names></name><name><surname>Vallance</surname> <given-names>H</given-names></name><name><surname>Stockler-Ipsiroglu</surname> <given-names>S</given-names></name><name><surname>Sinclair</surname> <given-names>G</given-names></name><name><surname>Wasserman</surname> <given-names>WW</given-names></name><name><surname>van Karnebeek</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Exome sequencing and the management of neurometabolic disorders</article-title><source>New England Journal of Medicine</source><volume>374</volume><fpage>2246</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1515792</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turro</surname> <given-names>E</given-names></name><name><surname>Astle</surname> <given-names>WJ</given-names></name><name><surname>Megy</surname> <given-names>K</given-names></name><name><surname>Gräf</surname> <given-names>S</given-names></name><name><surname>Greene</surname> <given-names>D</given-names></name><name><surname>Shamardina</surname> <given-names>O</given-names></name><name><surname>Allen</surname> <given-names>HL</given-names></name><name><surname>Sanchis-Juan</surname> <given-names>A</given-names></name><name><surname>Frontini</surname> <given-names>M</given-names></name><name><surname>Thys</surname> <given-names>C</given-names></name><name><surname>Stephens</surname> <given-names>J</given-names></name><name><surname>Mapeta</surname> <given-names>R</given-names></name><name><surname>Burren</surname> <given-names>OS</given-names></name><name><surname>Downes</surname> <given-names>K</given-names></name><name><surname>Haimel</surname> <given-names>M</given-names></name><name><surname>Tuna</surname> <given-names>S</given-names></name><name><surname>Deevi</surname> <given-names>SVV</given-names></name><name><surname>Aitman</surname> <given-names>TJ</given-names></name><name><surname>Bennett</surname> <given-names>DL</given-names></name><name><surname>Calleja</surname> <given-names>P</given-names></name><name><surname>Carss</surname> <given-names>K</given-names></name><name><surname>Caulfield</surname> <given-names>MJ</given-names></name><name><surname>Chinnery</surname> <given-names>PF</given-names></name><name><surname>Dixon</surname> <given-names>PH</given-names></name><name><surname>Gale</surname> <given-names>DP</given-names></name><name><surname>James</surname> <given-names>R</given-names></name><name><surname>Koziell</surname> <given-names>A</given-names></name><name><surname>Laffan</surname> <given-names>MA</given-names></name><name><surname>Levine</surname> <given-names>AP</given-names></name><name><surname>Maher</surname> <given-names>ER</given-names></name><name><surname>Markus</surname> <given-names>HS</given-names></name><name><surname>Morales</surname> <given-names>J</given-names></name><name><surname>Morrell</surname> <given-names>NW</given-names></name><name><surname>Mumford</surname> <given-names>AD</given-names></name><name><surname>Ormondroyd</surname> <given-names>E</given-names></name><name><surname>Rankin</surname> <given-names>S</given-names></name><name><surname>Rendon</surname> <given-names>A</given-names></name><name><surname>Richardson</surname> <given-names>S</given-names></name><name><surname>Roberts</surname> <given-names>I</given-names></name><name><surname>Roy</surname> <given-names>NBA</given-names></name><name><surname>Saleem</surname> <given-names>MA</given-names></name><name><surname>Smith</surname> <given-names>KGC</given-names></name><name><surname>Stark</surname> <given-names>H</given-names></name><name><surname>Tan</surname> <given-names>RYY</given-names></name><name><surname>Themistocleous</surname> <given-names>AC</given-names></name><name><surname>Thrasher</surname> <given-names>AJ</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Webster</surname> <given-names>AR</given-names></name><name><surname>Wilkins</surname> <given-names>MR</given-names></name><name><surname>Williamson</surname> <given-names>C</given-names></name><name><surname>Whitworth</surname> <given-names>J</given-names></name><name><surname>Humphray</surname> <given-names>S</given-names></name><name><surname>Bentley</surname> <given-names>DR</given-names></name><name><surname>Abbs</surname> <given-names>S</given-names></name><name><surname>Abulhoul</surname> <given-names>L</given-names></name><name><surname>Adlard</surname> <given-names>J</given-names></name><name><surname>Ahmed</surname> <given-names>M</given-names></name><name><surname>Aitman</surname> <given-names>TJ</given-names></name><name><surname>Alachkar</surname> <given-names>H</given-names></name><name><surname>Allsup</surname> <given-names>DJ</given-names></name><name><surname>Almeida-King</surname> <given-names>J</given-names></name><name><surname>Ancliff</surname> <given-names>P</given-names></name><name><surname>Antrobus</surname> <given-names>R</given-names></name><name><surname>Armstrong</surname> <given-names>R</given-names></name><name><surname>Arno</surname> <given-names>G</given-names></name><name><surname>Ashford</surname> <given-names>S</given-names></name><name><surname>Astle</surname> <given-names>WJ</given-names></name><name><surname>Attwood</surname> <given-names>A</given-names></name><name><surname>Aurora</surname> <given-names>P</given-names></name><name><surname>Babbs</surname> <given-names>C</given-names></name><name><surname>Bacchelli</surname> <given-names>C</given-names></name><name><surname>Bakchoul</surname> <given-names>T</given-names></name><name><surname>Banka</surname> <given-names>S</given-names></name><name><surname>Bariana</surname> <given-names>T</given-names></name><name><surname>Barwell</surname> <given-names>J</given-names></name><name><surname>Batista</surname> <given-names>J</given-names></name><name><surname>Baxendale</surname> <given-names>HE</given-names></name><name><surname>Beales</surname> <given-names>PL</given-names></name><name><surname>Bennett</surname> <given-names>DL</given-names></name><name><surname>Bentley</surname> <given-names>DR</given-names></name><name><surname>Bierzynska</surname> <given-names>A</given-names></name><name><surname>Biss</surname> <given-names>T</given-names></name><name><surname>Bitner-Glindzicz</surname> <given-names>MAK</given-names></name><name><surname>Black</surname> <given-names>GC</given-names></name><name><surname>Bleda</surname> <given-names>M</given-names></name><name><surname>Blesneac</surname> <given-names>I</given-names></name><name><surname>Bockenhauer</surname> <given-names>D</given-names></name><name><surname>Bogaard</surname> <given-names>H</given-names></name><name><surname>Bourne</surname> <given-names>CJ</given-names></name><name><surname>Boyce</surname> <given-names>S</given-names></name><name><surname>Bradley</surname> <given-names>JR</given-names></name><name><surname>Bragin</surname> <given-names>E</given-names></name><name><surname>Breen</surname> <given-names>G</given-names></name><name><surname>Brennan</surname> <given-names>P</given-names></name><name><surname>Brewer</surname> <given-names>C</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Browning</surname> <given-names>AC</given-names></name><name><surname>Browning</surname> <given-names>MJ</given-names></name><name><surname>Buchan</surname> <given-names>RJ</given-names></name><name><surname>Buckland</surname> <given-names>MS</given-names></name><name><surname>Bueser</surname> <given-names>T</given-names></name><name><surname>Diz</surname> <given-names>CB</given-names></name><name><surname>Burn</surname> <given-names>J</given-names></name><name><surname>Burns</surname> <given-names>SO</given-names></name><name><surname>Burren</surname> <given-names>OS</given-names></name><name><surname>Burrows</surname> <given-names>N</given-names></name><name><surname>Calleja</surname> <given-names>P</given-names></name><name><surname>Campbell</surname> <given-names>C</given-names></name><name><surname>Carr-White</surname> <given-names>G</given-names></name><name><surname>Carss</surname> <given-names>K</given-names></name><name><surname>Casey</surname> <given-names>R</given-names></name><name><surname>Caulfield</surname> <given-names>MJ</given-names></name><name><surname>Chambers</surname> <given-names>J</given-names></name><name><surname>Chambers</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>MMY</given-names></name><name><surname>Cheah</surname> <given-names>C</given-names></name><name><surname>Cheng</surname> <given-names>F</given-names></name><name><surname>Chinnery</surname> <given-names>PF</given-names></name><name><surname>Chitre</surname> <given-names>M</given-names></name><name><surname>Christian</surname> <given-names>MT</given-names></name><name><surname>Church</surname> <given-names>C</given-names></name><name><surname>Clayton-Smith</surname> <given-names>J</given-names></name><name><surname>Cleary</surname> <given-names>M</given-names></name><name><surname>Brod</surname> <given-names>NC</given-names></name><name><surname>Coghlan</surname> <given-names>G</given-names></name><name><surname>Colby</surname> <given-names>E</given-names></name><name><surname>Cole</surname> <given-names>TRP</given-names></name><name><surname>Collins</surname> <given-names>J</given-names></name><name><surname>Collins</surname> <given-names>PW</given-names></name><name><surname>Colombo</surname> <given-names>C</given-names></name><name><surname>Compton</surname> <given-names>CJ</given-names></name><name><surname>Condliffe</surname> <given-names>R</given-names></name><name><surname>Cook</surname> <given-names>S</given-names></name><name><surname>Cook</surname> <given-names>HT</given-names></name><name><surname>Cooper</surname> <given-names>N</given-names></name><name><surname>Corris</surname> <given-names>PA</given-names></name><name><surname>Furnell</surname> <given-names>A</given-names></name><name><surname>Cunningham</surname> <given-names>F</given-names></name><name><surname>Curry</surname> <given-names>NS</given-names></name><name><surname>Cutler</surname> <given-names>AJ</given-names></name><name><surname>Daniels</surname> <given-names>MJ</given-names></name><name><surname>Dattani</surname> <given-names>M</given-names></name><name><surname>Daugherty</surname> <given-names>LC</given-names></name><name><surname>Davis</surname> <given-names>J</given-names></name><name><surname>De Soyza</surname> <given-names>A</given-names></name><name><surname>Deevi</surname> <given-names>SVV</given-names></name><name><surname>Dent</surname> <given-names>T</given-names></name><name><surname>Deshpande</surname> <given-names>C</given-names></name><name><surname>Dewhurst</surname> <given-names>EF</given-names></name><name><surname>Dixon</surname> <given-names>PH</given-names></name><name><surname>Douzgou</surname> <given-names>S</given-names></name><name><surname>Downes</surname> <given-names>K</given-names></name><name><surname>Drazyk</surname> <given-names>AM</given-names></name><name><surname>Drewe</surname> <given-names>E</given-names></name><name><surname>Duarte</surname> <given-names>D</given-names></name><name><surname>Dutt</surname> <given-names>T</given-names></name><name><surname>Edgar</surname> <given-names>JDM</given-names></name><name><surname>Edwards</surname> <given-names>K</given-names></name><name><surname>Egner</surname> <given-names>W</given-names></name><name><surname>Ekani</surname> <given-names>MN</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Erber</surname> <given-names>WN</given-names></name><name><surname>Erwood</surname> <given-names>M</given-names></name><name><surname>Estiu</surname> <given-names>MC</given-names></name><name><surname>Evans</surname> <given-names>DG</given-names></name><name><surname>Evans</surname> <given-names>G</given-names></name><name><surname>Everington</surname> <given-names>T</given-names></name><name><surname>Eyries</surname> <given-names>M</given-names></name><name><surname>Fassihi</surname> <given-names>H</given-names></name><name><surname>Favier</surname> <given-names>R</given-names></name><name><surname>Findhammer</surname> <given-names>J</given-names></name><name><surname>Fletcher</surname> <given-names>D</given-names></name><name><surname>Flinter</surname> <given-names>FA</given-names></name><name><surname>Floto</surname> <given-names>RA</given-names></name><name><surname>Fowler</surname> <given-names>T</given-names></name><name><surname>Fox</surname> <given-names>J</given-names></name><name><surname>Frary</surname> <given-names>AJ</given-names></name><name><surname>French</surname> <given-names>CE</given-names></name><name><surname>Freson</surname> <given-names>K</given-names></name><name><surname>Frontini</surname> <given-names>M</given-names></name><name><surname>Gale</surname> <given-names>DP</given-names></name><name><surname>Gall</surname> <given-names>H</given-names></name><name><surname>Ganesan</surname> <given-names>V</given-names></name><name><surname>Gattens</surname> <given-names>M</given-names></name><name><surname>Geoghegan</surname> <given-names>C</given-names></name><name><surname>Gerighty</surname> <given-names>TSA</given-names></name><name><surname>Gharavi</surname> <given-names>AG</given-names></name><name><surname>Ghio</surname> <given-names>S</given-names></name><name><surname>Ghofrani</surname> <given-names>H-A</given-names></name><name><surname>Gibbs</surname> <given-names>JSR</given-names></name><name><surname>Gibson</surname> <given-names>K</given-names></name><name><surname>Gilmour</surname> <given-names>KC</given-names></name><name><surname>Girerd</surname> <given-names>B</given-names></name><name><surname>Gleadall</surname> <given-names>NS</given-names></name><name><surname>Goddard</surname> <given-names>S</given-names></name><name><surname>Goldstein</surname> <given-names>DB</given-names></name><name><surname>Gomez</surname> <given-names>K</given-names></name><name><surname>Gordins</surname> <given-names>P</given-names></name><name><surname>Gosal</surname> <given-names>D</given-names></name><name><surname>Gräf</surname> <given-names>S</given-names></name><name><surname>Graham</surname> <given-names>J</given-names></name><name><surname>Grassi</surname> <given-names>L</given-names></name><name><surname>Greene</surname> <given-names>D</given-names></name><name><surname>Greenhalgh</surname> <given-names>L</given-names></name><name><surname>Greinacher</surname> <given-names>A</given-names></name><name><surname>Gresele</surname> <given-names>P</given-names></name><name><surname>Griffiths</surname> <given-names>P</given-names></name><name><surname>Grigoriadou</surname> <given-names>S</given-names></name><name><surname>Grocock</surname> <given-names>RJ</given-names></name><name><surname>Grozeva</surname> <given-names>D</given-names></name><name><surname>Gurnell</surname> <given-names>M</given-names></name><name><surname>Hackett</surname> <given-names>S</given-names></name><name><surname>Hadinnapola</surname> <given-names>C</given-names></name><name><surname>Hague</surname> <given-names>WM</given-names></name><name><surname>Hague</surname> <given-names>R</given-names></name><name><surname>Haimel</surname> <given-names>M</given-names></name><name><surname>Hall</surname> <given-names>M</given-names></name><name><surname>Hanson</surname> <given-names>HL</given-names></name><name><surname>Haque</surname> <given-names>E</given-names></name><name><surname>Harkness</surname> <given-names>K</given-names></name><name><surname>Harper</surname> <given-names>AR</given-names></name><name><surname>Harris</surname> <given-names>CL</given-names></name><name><surname>Hart</surname> <given-names>D</given-names></name><name><surname>Hassan</surname> <given-names>A</given-names></name><name><surname>Hayman</surname> <given-names>G</given-names></name><name><surname>Henderson</surname> <given-names>A</given-names></name><name><surname>Herwadkar</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>J</given-names></name><name><surname>Holden</surname> <given-names>S</given-names></name><name><surname>Horvath</surname> <given-names>R</given-names></name><name><surname>Houlden</surname> <given-names>H</given-names></name><name><surname>Houweling</surname> <given-names>AC</given-names></name><name><surname>Howard</surname> <given-names>LS</given-names></name><name><surname>Hu</surname> <given-names>F</given-names></name><name><surname>Hudson</surname> <given-names>G</given-names></name><name><surname>Hughes</surname> <given-names>J</given-names></name><name><surname>Huissoon</surname> <given-names>AP</given-names></name><name><surname>Humbert</surname> <given-names>M</given-names></name><name><surname>Humphray</surname> <given-names>S</given-names></name><name><surname>Hunter</surname> <given-names>S</given-names></name><name><surname>Hurles</surname> <given-names>M</given-names></name><name><surname>Irving</surname> <given-names>M</given-names></name><name><surname>Izatt</surname> <given-names>L</given-names></name><name><surname>James</surname> <given-names>R</given-names></name><name><surname>Johnson</surname> <given-names>SA</given-names></name><name><surname>Jolles</surname> <given-names>S</given-names></name><name><surname>Jolley</surname> <given-names>J</given-names></name><name><surname>Josifova</surname> <given-names>D</given-names></name><name><surname>Jurkute</surname> <given-names>N</given-names></name><name><surname>Karten</surname> <given-names>T</given-names></name><name><surname>Karten</surname> <given-names>J</given-names></name><name><surname>Kasanicki</surname> <given-names>MA</given-names></name><name><surname>Kazkaz</surname> <given-names>H</given-names></name><name><surname>Kazmi</surname> <given-names>R</given-names></name><name><surname>Kelleher</surname> <given-names>P</given-names></name><name><surname>Kelly</surname> <given-names>AM</given-names></name><name><surname>Kelsall</surname> <given-names>W</given-names></name><name><surname>Kempster</surname> <given-names>C</given-names></name><name><surname>Kiely</surname> <given-names>DG</given-names></name><name><surname>Kingston</surname> <given-names>N</given-names></name><name><surname>Klima</surname> <given-names>R</given-names></name><name><surname>Koelling</surname> <given-names>N</given-names></name><name><surname>Kostadima</surname> <given-names>M</given-names></name><name><surname>Kovacs</surname> <given-names>G</given-names></name><name><surname>Koziell</surname> <given-names>A</given-names></name><name><surname>Kreuzhuber</surname> <given-names>R</given-names></name><name><surname>Kuijpers</surname> <given-names>TW</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name><name><surname>Kumararatne</surname> <given-names>D</given-names></name><name><surname>Kurian</surname> <given-names>MA</given-names></name><name><surname>Laffan</surname> <given-names>MA</given-names></name><name><surname>Lalloo</surname> <given-names>F</given-names></name><name><surname>Lambert</surname> <given-names>M</given-names></name><name><surname>Allen</surname> <given-names>HL</given-names></name><name><surname>Lawrie</surname> <given-names>A</given-names></name><name><surname>Layton</surname> <given-names>DM</given-names></name><name><surname>Lench</surname> <given-names>N</given-names></name><name><surname>Lentaigne</surname> <given-names>C</given-names></name><name><surname>Lester</surname> <given-names>T</given-names></name><name><surname>Levine</surname> <given-names>AP</given-names></name><name><surname>Linger</surname> <given-names>R</given-names></name><name><surname>Longhurst</surname> <given-names>H</given-names></name><name><surname>Lorenzo</surname> <given-names>LE</given-names></name><name><surname>Louka</surname> <given-names>E</given-names></name><name><surname>Lyons</surname> <given-names>PA</given-names></name><name><surname>Machado</surname> <given-names>RD</given-names></name><name><surname>MacKenzie Ross</surname> <given-names>RV</given-names></name><name><surname>Madan</surname> <given-names>B</given-names></name><name><surname>Maher</surname> <given-names>ER</given-names></name><name><surname>Maimaris</surname> <given-names>J</given-names></name><name><surname>Malka</surname> <given-names>S</given-names></name><name><surname>Mangles</surname> <given-names>S</given-names></name><name><surname>Mapeta</surname> <given-names>R</given-names></name><name><surname>Marchbank</surname> <given-names>KJ</given-names></name><name><surname>Marks</surname> <given-names>S</given-names></name><name><surname>Markus</surname> <given-names>HS</given-names></name><name><surname>Marschall</surname> <given-names>H-U</given-names></name><name><surname>Marshall</surname> <given-names>A</given-names></name><name><surname>Martin</surname> <given-names>J</given-names></name><name><surname>Mathias</surname> <given-names>M</given-names></name><name><surname>Matthews</surname> <given-names>E</given-names></name><name><surname>Maxwell</surname> <given-names>H</given-names></name><name><surname>McAlinden</surname> <given-names>P</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>McKinney</surname> <given-names>H</given-names></name><name><surname>McMahon</surname> <given-names>A</given-names></name><name><surname>Meacham</surname> <given-names>S</given-names></name><name><surname>Mead</surname> <given-names>AJ</given-names></name><name><surname>Castello</surname> <given-names>IM</given-names></name><name><surname>Megy</surname> <given-names>K</given-names></name><name><surname>Mehta</surname> <given-names>SG</given-names></name><name><surname>Michaelides</surname> <given-names>M</given-names></name><name><surname>Millar</surname> <given-names>C</given-names></name><name><surname>Mohammed</surname> <given-names>SN</given-names></name><name><surname>Moledina</surname> <given-names>S</given-names></name><name><surname>Montani</surname> <given-names>D</given-names></name><name><surname>Moore</surname> <given-names>AT</given-names></name><name><surname>Morales</surname> <given-names>J</given-names></name><name><surname>Morrell</surname> <given-names>NW</given-names></name><name><surname>Mozere</surname> <given-names>M</given-names></name><name><surname>Muir</surname> <given-names>KW</given-names></name><name><surname>Mumford</surname> <given-names>AD</given-names></name><name><surname>Nemeth</surname> <given-names>AH</given-names></name><name><surname>Newman</surname> <given-names>WG</given-names></name><name><surname>Newnham</surname> <given-names>M</given-names></name><name><surname>Noorani</surname> <given-names>S</given-names></name><name><surname>Nurden</surname> <given-names>P</given-names></name><name><surname>O’Sullivan</surname> <given-names>J</given-names></name><name><surname>Obaji</surname> <given-names>S</given-names></name><name><surname>Odhams</surname> <given-names>C</given-names></name><name><surname>Okoli</surname> <given-names>S</given-names></name><name><surname>Olschewski</surname> <given-names>A</given-names></name><name><surname>Olschewski</surname> <given-names>H</given-names></name><name><surname>Ong</surname> <given-names>KR</given-names></name><name><surname>Oram</surname> <given-names>SH</given-names></name><name><surname>Ormondroyd</surname> <given-names>E</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Palles</surname> <given-names>C</given-names></name><name><surname>Papadia</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>S-M</given-names></name><name><surname>Parry</surname> <given-names>D</given-names></name><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Paterson</surname> <given-names>J</given-names></name><name><surname>Peacock</surname> <given-names>A</given-names></name><name><surname>Pearce</surname> <given-names>SH</given-names></name><name><surname>Peden</surname> <given-names>J</given-names></name><name><surname>Peerlinck</surname> <given-names>K</given-names></name><name><surname>Penkett</surname> <given-names>CJ</given-names></name><name><surname>Pepke-Zaba</surname> <given-names>J</given-names></name><name><surname>Petersen</surname> <given-names>R</given-names></name><name><surname>Pilkington</surname> <given-names>C</given-names></name><name><surname>Poole</surname> <given-names>KES</given-names></name><name><surname>Prathalingam</surname> <given-names>R</given-names></name><name><surname>Psaila</surname> <given-names>B</given-names></name><name><surname>Pyle</surname> <given-names>A</given-names></name><name><surname>Quinton</surname> <given-names>R</given-names></name><name><surname>Rahman</surname> <given-names>S</given-names></name><name><surname>Rankin</surname> <given-names>S</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Raymond</surname> <given-names>FL</given-names></name><name><surname>Rayner-Matthews</surname> <given-names>PJ</given-names></name><name><surname>Rees</surname> <given-names>C</given-names></name><name><surname>Rendon</surname> <given-names>A</given-names></name><name><surname>Renton</surname> <given-names>T</given-names></name><name><surname>Rhodes</surname> <given-names>CJ</given-names></name><name><surname>Rice</surname> <given-names>ASC</given-names></name><name><surname>Richardson</surname> <given-names>S</given-names></name><name><surname>Richter</surname> <given-names>A</given-names></name><name><surname>Robert</surname> <given-names>L</given-names></name><name><surname>Roberts</surname> <given-names>I</given-names></name><name><surname>Rogers</surname> <given-names>A</given-names></name><name><surname>Rose</surname> <given-names>SJ</given-names></name><name><surname>Ross-Russell</surname> <given-names>R</given-names></name><name><surname>Roughley</surname> <given-names>C</given-names></name><name><surname>Roy</surname> <given-names>NBA</given-names></name><name><surname>Ruddy</surname> <given-names>DM</given-names></name><name><surname>Sadeghi-Alavijeh</surname> <given-names>O</given-names></name><name><surname>Saleem</surname> <given-names>MA</given-names></name><name><surname>Samani</surname> <given-names>N</given-names></name><name><surname>Samarghitean</surname> <given-names>C</given-names></name><name><surname>Sanchis-Juan</surname> <given-names>A</given-names></name><name><surname>Sargur</surname> <given-names>RB</given-names></name><name><surname>Sarkany</surname> <given-names>RN</given-names></name><name><surname>Satchell</surname> <given-names>S</given-names></name><name><surname>Savic</surname> <given-names>S</given-names></name><name><surname>Sayer</surname> <given-names>JA</given-names></name><name><surname>Sayer</surname> <given-names>G</given-names></name><name><surname>Scelsi</surname> <given-names>L</given-names></name><name><surname>Schaefer</surname> <given-names>AM</given-names></name><name><surname>Schulman</surname> <given-names>S</given-names></name><name><surname>Scott</surname> <given-names>R</given-names></name><name><surname>Scully</surname> <given-names>M</given-names></name><name><surname>Searle</surname> <given-names>C</given-names></name><name><surname>Seeger</surname> <given-names>W</given-names></name><name><surname>Sen</surname> <given-names>A</given-names></name><name><surname>Sewell</surname> <given-names>WAC</given-names></name><name><surname>Seyres</surname> <given-names>D</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Shamardina</surname> <given-names>O</given-names></name><name><surname>Shapiro</surname> <given-names>SE</given-names></name><name><surname>Shaw</surname> <given-names>AC</given-names></name><name><surname>Short</surname> <given-names>PJ</given-names></name><name><surname>Sibson</surname> <given-names>K</given-names></name><name><surname>Side</surname> <given-names>L</given-names></name><name><surname>Simeoni</surname> <given-names>I</given-names></name><name><surname>Simpson</surname> <given-names>MA</given-names></name><name><surname>Sims</surname> <given-names>MC</given-names></name><name><surname>Sivapalaratnam</surname> <given-names>S</given-names></name><name><surname>Smedley</surname> <given-names>D</given-names></name><name><surname>Smith</surname> <given-names>KR</given-names></name><name><surname>Smith</surname> <given-names>KGC</given-names></name><name><surname>Snape</surname> <given-names>K</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name><name><surname>Soubrier</surname> <given-names>F</given-names></name><name><surname>Southgate</surname> <given-names>L</given-names></name><name><surname>Spasic-Boskovic</surname> <given-names>O</given-names></name><name><surname>Staines</surname> <given-names>S</given-names></name><name><surname>Staples</surname> <given-names>E</given-names></name><name><surname>Stark</surname> <given-names>H</given-names></name><name><surname>Stephens</surname> <given-names>J</given-names></name><name><surname>Steward</surname> <given-names>C</given-names></name><name><surname>Stirrups</surname> <given-names>KE</given-names></name><name><surname>Stuckey</surname> <given-names>A</given-names></name><name><surname>Suntharalingam</surname> <given-names>J</given-names></name><name><surname>Swietlik</surname> <given-names>EM</given-names></name><name><surname>Syrris</surname> <given-names>P</given-names></name><name><surname>Tait</surname> <given-names>RC</given-names></name><name><surname>Talks</surname> <given-names>K</given-names></name><name><surname>Tan</surname> <given-names>RYY</given-names></name><name><surname>Tate</surname> <given-names>K</given-names></name><name><surname>Taylor</surname> <given-names>JM</given-names></name><name><surname>Taylor</surname> <given-names>JC</given-names></name><name><surname>Thaventhiran</surname> <given-names>JE</given-names></name><name><surname>Themistocleous</surname> <given-names>AC</given-names></name><name><surname>Thomas</surname> <given-names>E</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Thomas</surname> <given-names>MJ</given-names></name><name><surname>Thomas</surname> <given-names>P</given-names></name><name><surname>Thomson</surname> <given-names>K</given-names></name><name><surname>Thrasher</surname> <given-names>AJ</given-names></name><name><surname>Threadgold</surname> <given-names>G</given-names></name><name><surname>Thys</surname> <given-names>C</given-names></name><name><surname>Tilly</surname> <given-names>T</given-names></name><name><surname>Tischkowitz</surname> <given-names>M</given-names></name><name><surname>Titterton</surname> <given-names>C</given-names></name><name><surname>Todd</surname> <given-names>JA</given-names></name><name><surname>Toh</surname> <given-names>C-H</given-names></name><name><surname>Tolhuis</surname> <given-names>B</given-names></name><name><surname>Tomlinson</surname> <given-names>IP</given-names></name><name><surname>Toshner</surname> <given-names>M</given-names></name><name><surname>Traylor</surname> <given-names>M</given-names></name><name><surname>Treacy</surname> <given-names>C</given-names></name><name><surname>Treadaway</surname> <given-names>P</given-names></name><name><surname>Trembath</surname> <given-names>R</given-names></name><name><surname>Tuna</surname> <given-names>S</given-names></name><name><surname>Turek</surname> <given-names>W</given-names></name><name><surname>Turro</surname> <given-names>E</given-names></name><name><surname>Twiss</surname> <given-names>P</given-names></name><name><surname>Vale</surname> <given-names>T</given-names></name><name><surname>Geet</surname> <given-names>CV</given-names></name><name><surname>Zuydam</surname> <given-names>Nvan</given-names></name><name><surname>Vandekuilen</surname> <given-names>M</given-names></name><name><surname>Vandersteen</surname> <given-names>AM</given-names></name><name><surname>Vazquez-Lopez</surname> <given-names>M</given-names></name><name><surname>von Ziegenweidt</surname> <given-names>J</given-names></name><name><surname>Vonk Noordegraaf</surname> <given-names>A</given-names></name><name><surname>Wagner</surname> <given-names>A</given-names></name><name><surname>Waisfisz</surname> <given-names>Q</given-names></name><name><surname>Walker</surname> <given-names>SM</given-names></name><name><surname>Walker</surname> <given-names>N</given-names></name><name><surname>Walter</surname> <given-names>K</given-names></name><name><surname>Ware</surname> <given-names>JS</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Watt</surname> <given-names>C</given-names></name><name><surname>Webster</surname> <given-names>AR</given-names></name><name><surname>Wedderburn</surname> <given-names>L</given-names></name><name><surname>Wei</surname> <given-names>W</given-names></name><name><surname>Welch</surname> <given-names>SB</given-names></name><name><surname>Wessels</surname> <given-names>J</given-names></name><name><surname>Westbury</surname> <given-names>SK</given-names></name><name><surname>Westwood</surname> <given-names>J-P</given-names></name><name><surname>Wharton</surname> <given-names>J</given-names></name><name><surname>Whitehorn</surname> <given-names>D</given-names></name><name><surname>Whitworth</surname> <given-names>J</given-names></name><name><surname>Wilkie</surname> <given-names>AOM</given-names></name><name><surname>Wilkins</surname> <given-names>MR</given-names></name><name><surname>Williamson</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>BT</given-names></name><name><surname>Wong</surname> <given-names>EKS</given-names></name><name><surname>Wood</surname> <given-names>N</given-names></name><name><surname>Wood</surname> <given-names>Y</given-names></name><name><surname>Woods</surname> <given-names>CG</given-names></name><name><surname>Woodward</surname> <given-names>ER</given-names></name><name><surname>Wort</surname> <given-names>SJ</given-names></name><name><surname>Worth</surname> <given-names>A</given-names></name><name><surname>Wright</surname> <given-names>M</given-names></name><name><surname>Yates</surname> <given-names>K</given-names></name><name><surname>Yong</surname> <given-names>PFK</given-names></name><name><surname>Young</surname> <given-names>T</given-names></name><name><surname>Yu</surname> <given-names>P</given-names></name><name><surname>Yu-Wai-Man</surname> <given-names>P</given-names></name><name><surname>Zlamalova</surname> <given-names>E</given-names></name><name><surname>Kingston</surname> <given-names>N</given-names></name><name><surname>Walker</surname> <given-names>N</given-names></name><name><surname>Bradley</surname> <given-names>JR</given-names></name><name><surname>Ashford</surname> <given-names>S</given-names></name><name><surname>Penkett</surname> <given-names>CJ</given-names></name><name><surname>Freson</surname> <given-names>K</given-names></name><name><surname>Stirrups</surname> <given-names>KE</given-names></name><name><surname>Raymond</surname> <given-names>FL</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Whole-genome sequencing of patients with rare diseases in a national health system</article-title><source>Nature</source><volume>583</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2434-2</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67097.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Narla</surname><given-names>Goutham</given-names></name><role>Reviewing Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The study elegantly demonstrates the use of an FDA-approved drug, Eflornithine, to treat, with considerable success, the neurological and skin manifestations of a child with a gain of function mutation of the ODC1 gene. The authors have addressed all of our concerns/comments and the manuscript in its revised form is now acceptable for publication at e<italic>Life.</italic><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Repurposing Eflornithine to Treat a Patient with a Rare ODC1 Gain of Function Variant Disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>There was significant interest in the work overall as noted below from comments from both reviewers – the repurposing of FDA approved to treat existing diseases is of great interest to the scientific and medical community. There are however several issues that need to be addressed prior to the acceptance of this manuscript to e<italic>Life</italic>.</p><p>1) Where there side effects associated with administration of the drug and if so those be noted and described in detail with laboratory values/data provided when available</p><p>2) While the work is of interest a single case is presented, were additional patients treated and if so what was their outcome?</p><p><italic>Reviewer #1:</italic></p><p>In the present study, Rajasekaran et al. describe the clinical findings resulting from repurposing Eflornithine (ODC inhibitor), an FDA approved drug, for a metabolic rare disease caused by pathogenic gain-of-function variants in ODC1. Based on their previous case report (PMID: 30239107), the authors observed that the clinical findings of their patient (alopecia, brain and scalp cystic lesions, and a variety of metabolites) improved after Eflornithine treatment. The study provides intriguing new insights into the treatment of this ultra-rare condition, and highlights the success of repurposing drugs for metabolic disease, but is limited by the single patient treated and lack of information about side effects.</p><p>1. Eflornithine is an inhibitor of ODC. Were there any side effects observed in the patient during the treatment process, especially during the period of dosage adjustment?</p><p>2. Myelosuppression is common in patients taking Eflornithine. Were complete blood cell counts measured before, during, and after the treatment? These should be included in the report.</p><p>3. Did the protein level of ODC change before and after treatment?</p><p>4. In the Discussion section, the authors mention the possibility of replication of findings in the current study in other patients with ODC1 gain-of-function. There is another report of 4 individuals with ODC1 gain-of-function variants (PMID: 30475435) which highlights the variable expressivity present among patients with this disorder. Replicating their findings in some of these other patients seems necessary before drawing conclusions about the efficacy of Eflornithine for effectively treating the clinical features of ODC1 gain-of-function variants. This is especially important since the authors were unable to perform neurological assessments for their study.</p><p><italic>Reviewer #3:</italic></p><p>This is an excellent paper which describes a rational and effective treatment for a very rare inherited condition.</p><p>The authors explain clearly the reasons for their using the drug selected based on the available literature with a transgenic mouse model and show very encouraging preliminary results that it will be effective.</p><p>There are a few corrections/additions which should be made to the manuscript.</p><p>1. The sentence starting on line 58 is ambiguous. Are there for additional patients with similar mutations that have been reported and four more cases or is the total number of cases actually known at present.</p><p>2. Some details of the low polyamine diet that was co-administered with the drug should be given and some discussion of whether this is likely to be a critical issue in the success of the treatment are needed. Since, as described in the paper, polyamine levels are intricately controlled by regulation of synthesis, degradation and uptake, it seems unlikely that uptake dietary polyamines would be a major issue in this condition which involves high levels that would be expected to suppress uptake.</p><p>3. Figure 2C would be very confusing to anyone not familiar with the ODC structure. It needs a longer explanation in either the text or the figure legend explaining that the protein is made up of two identical subunits which form to active sites at their interface. Showing the two subunits in different colors would be helpful. it is also confusing to show the two ends in different formulations without clearly explaining why this is done. The text would better if it referred to the two ODC monomers than two ODC proteins</p><p>A reference to the structure is needed eg for human (Almrud, J. J., Oliveira, M. A., Kern, A. D., Grishin, N. V., Phillips, M. A., and Hackert, M. L. (2000) Crystal structure of human ornithine decarboxylase at 2.1 Å resolution: structural insights to antizyme binding. J. Mol. Biol. 295, 7-16 ) or mouse (Kern, A. D., Oliveira, M. A., Coffino, P., and Hackert, M. L. (1999) Structure of mammalian ornithine decarboxylase at 1.6 Å resolution: stereochemical implications of PLP-dependent amino acid decarboxylases. Structure 7, 567-581).</p><p>4. A reference to the original work of the very gifted chemists and pharmacologists that lead to the conceptualization and production of DFMO would be appropriate. For example, Metcalf, B. W., Bey, P., Danzin, C., Jung, M. J., Casara, P., and Vevert, J. P. (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E. C. 4. 1. 1. 17) by substrate and product analogues. J. Am. Chem. Soc. 100, 2551-2553.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67097.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>There was significant interest in the work overall as noted below from comments from both reviewers – the repurposing of FDA approved to treat existing diseases is of great interest to the scientific and medical community. There are however several issues that need to be addressed prior to the acceptance of this manuscript to eLife.</p><p>1) Were there side effects associated with administration of the drug and if so those be noted and described in detail with laboratory values/data provided when available</p></disp-quote><p>Additional information about the safety screening procedure for this treatment is now included. No abnormalities were noted from any of the laboratory values monitored, and there were no clinically apparent side effects observed throughout this treatment. An updated paragraph detailing this information is now included both in methods section and the patient’s experience in the result section of the manuscript.</p><p>Methods section “These draws were performed in conjunction with safety screening that included at baseline, weekly after each dose increase and then twice monthly, which included a complete blood count, liver function test, lactate dehydrogenase, complete metabolic panel, calcium, magnesium, and phosphate. Audiograms were obtained pretreatment and then monthly. Electrocardiograms were done pretreatment, 1 month after first dose, and every 6 months, all based upon guidance from previous pediatric treatment trials with DFMO<sup>10</sup>”</p><p>In the Results section “All pre-treatment testing results were within normal limits, and through the duration of treatment, no abnormalities were noted in any of the described safety monitoring. This includes no gastrointestinal adverse effects or myelosuppression, previously noted in patients treated with DFMO.”</p><disp-quote content-type="editor-comment"><p>2) While the work is of interest a single case is presented, were additional patients treated and if so what was their outcome?</p></disp-quote><p>No, as with most rare diseases, we have a unique situation but there are new patients being identified with potential for benefit from DFMO treatment. These patients are in other locations receiving healthcare from other Institutions. The process of initiating DFMO needs careful planning and FDA involvement. We hope to continue to understand this condition with the potential for expanded treatment, one day. The publication of this report will go a long way to shed light on this rare disorder and highlight potential for therapy. To the best of our knowledge, there are currently no other patients with this disorder that have been treated with DFMO.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>In the present study, Rajasekaran et al. describe the clinical findings resulting from repurposing Eflornithine (ODC inhibitor), an FDA approved drug, for a metabolic rare disease caused by pathogenic gain-of-function variants in ODC1. Based on their previous case report (PMID: 30239107), the authors observed that the clinical findings of their patient (alopecia, brain and scalp cystic lesions, and a variety of metabolites) improved after Eflornithine treatment. The study provides intriguing new insights into the treatment of this ultra-rare condition, and highlights the success of repurposing drugs for metabolic disease, but is limited by the single patient treated and lack of information about side effects.</p><p>1. Eflornithine is an inhibitor of ODC. Were there any side effects observed in the patient during the treatment process, especially during the period of dosage adjustment?</p></disp-quote><p>We thank reviewer 1 for identifying this shortcoming as did the prior reviewer. Please see our response to as we did not identify any adverse effects to the patient during this treatment. Statements to that are now in both the methods and Results section.</p><disp-quote content-type="editor-comment"><p>2. Myelosuppression is common in patients taking Eflornithine. Were complete blood cell counts measured before, during, and after the treatment? These should be included in the report.</p></disp-quote><p>Complete blood counts were part of the safety monitoring during this treatment, and we did have access to other historical CBC results for this patient. There was no observed difference in counts during treatment, and a specific comment has been added to the manuscript noting this as it is an important matter to comment on.</p><disp-quote content-type="editor-comment"><p>3. Did the protein level of ODC change before and after treatment?</p></disp-quote><p>This is an excellent question and this is a limitation. We had previously measured the ODC levels of this patient in red blood cells and primary dermal skin fibroblasts before treatment and its response to DFMO. The previous publications showed both ODC proteins and enzymatic activity were significantly elevated compared to healthy controls and the levels dropped after DFMO. This is consistent with the hypothesis that the C-terminally deleted ODC leads to accumulated and active ODC protein in the patient (due to failure of the proteasome to clear the protein), resembling a gain-of-function (GOF) mutation. These observations were published prior to this study (Bupp et al., AMJG, 2018; Schultz et al., Biochem J, 2019). The use of western blot to measure protein levels has remained the traditional pathway to detect levels of intermediates before designing therapies for rare diseases. In this case we used the information from the previous study supported with global metabolomics done at different timepoints during therapy to determine that Putrescine was indeed elevated and dropped on therapy. After discussions with the FDA we pursued therapy through the more rapid compassionate use mechanism. Our hope is that this manuscript will highlight this approach as a model for using repurposed drug therapy rapidly with rapid advances in genetic diagnostics and need for rare disease treatments.</p><p>A statement is now added to the discussion as a limitation that says: “A limitation of this study is that we did not specifically measure enzymatic levels. In rare diseases, the enzyme activity and the resultant metabolic perturbation are traditionally studied in bench settings by detecting biochemical changes in the patient’s biological samples. This study used global metabolomics to measure polyamine levels serially as the patient underwent therapy.”.</p><disp-quote content-type="editor-comment"><p>4. In the Discussion section, the authors mention the possibility of replication of findings in the current study in other patients with ODC1 gain-of-function. There is another report of 4 individuals with ODC1 gain-of-function variants (PMID: 30475435) which highlights the variable expressivity present among patients with this disorder. Replicating their findings in some of these other patients seems necessary before drawing conclusions about the efficacy of Eflornithine for effectively treating the clinical features of ODC1 gain-of-function variants. This is especially important since the authors were unable to perform neurological assessments for their study.</p></disp-quote><p>Indeed, the phenotype may be variable, and the exact metabolic derangements need careful examination before therapy is initiated. We knew from the cell studies that she exhibited gain of function dyshomeostasis. In addition we utilized global metabolomics to map out the derangements at multiple timepoints. The presence of CAP/CLIA mandates allows the results to be reported in the Electronic Medical Record and allows treating physician to indeed initiate treatments. Our hope is that this initial manuscript highlights an approach that is more clinically practical in laying the groundwork for additional study and serves as a model for other ‘n of 1’ treatments.</p><p>One of the main limitations in rare disease research is the recruitment of patients from all over the world even if several have been identified, the challenge becomes how to get patients’ local hospital systems interested in novel trials particularly when these are often non-academic settings and how to balance the costs to families if recruitment is out of network or requires extensive travel. Thus, our hope is that this paper could open the possibility of navigating these challenges. In addition global metabolomics can be used to characterize the dyshomeostasis in each of these patients in the original healthcare institution.</p><p>A statement has now been added to the discussion that says “There are challenges in treating patients with rare diseases as the exact phenotype may be quite variable and the exact metabolic profile needs to be first established. Once therapy is indicated then the healthcare institution needs to be willing to navigate the regulatory hurdles to make the specific agent available for a single patient<bold>.”</bold></p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>This is an excellent paper which describes a rational and effective treatment for a very rare inherited condition.</p><p>The authors explain clearly the reasons for their using the drug selected based on the available literature with a transgenic mouse model and show very encouraging preliminary results that it will be effective.</p><p>There are a few corrections/additions which should be made to the manuscript.</p><p>1. The sentence starting on line 58 is ambiguous. Are there for additional patients with similar mutations that have been reported and four more cases or is the total number of cases actually known at present.</p></disp-quote><p>We agree that this sentence is poorly worded and confusing to the reader. There are four additional patients with similar mutations that were reported by Rodan et al. in 2018 as well as four more cases that have been identified but not yet reported. We will edit the sentence in line 58 to clarify this statement.</p><p>It now reads “Four additional patients with similar mutations and phenotypic features of this syndrome have since been reported<sup>4</sup> with at least four more cases identified in other centers, but not yet reported”.</p><disp-quote content-type="editor-comment"><p>2. Some details of the low polyamine diet that was co-administered with the drug should be given and some discussion of whether this is likely to be a critical issue in the success of the treatment are needed. Since, as described in the paper, polyamine levels are intricately controlled by regulation of synthesis, degradation and uptake, it seems unlikely that uptake dietary polyamines would be a major issue in this condition which involves high levels that would be expected to suppress uptake.</p></disp-quote><p>The consideration of polyamines in diet, its impact with this syndrome, and the potential role during treatment is an excellent point. Considering this suggestion, we reviewed the diet of this patient further with her family. We provided them a list of foods that are high in Polyamines to avoid. The patient reported in this manuscript has significant developmental delay and receives most of her nutrition through formula (Pediasure) given through gastrostomy tube. Her diet remained unchanged during the study.</p><p>We added a sentence in the methods and in the discussion on our recommendation to the family to avoid dietary items that have a high Polyamine content. “The family was provided a list of high polyamine containing food to avoid and therapy with DFMO initiated”.</p><disp-quote content-type="editor-comment"><p>3. Figure 2C would be very confusing to anyone not familiar with the ODC structure. It needs a longer explanation in either the text or the figure legend explaining that the protein is made up of two identical subunits which form to active sites at their interface. Showing the two subunits in different colors would be helpful. it is also confusing to show the two ends in different formulations without clearly explaining why this is done. The text would better if it referred to the two ODC monomers than two ODC proteins</p></disp-quote><p>Thank You reviewer 3, This is now done. We have changed the text to refer to monomer units, changed one of the monomers to green, and added the following sentence to clarify the structure model interpretation, “The protein in figure 2C shows one of the monomers as a surface plot in gray and the second monomer in secondary structure in green, with the region of the patient removed colored in red.” We wish to point out to the reviewers that neither of the structures mentioned contain the C-terminal amino acids, and thus we did not use either of these structures alone. To get this model we utilized a nonbiased multi model homology strategy that filled in the end regions with loop samples. We have added into the methods the following sentence: “Protein model of ODC dimer was generated using a merge of PDB files 1D7K, 2OO0, and 2ON3 with samplings of other PDB files to fill in the C-terminal region, followed by relaxation of bonds with the YASARA2 force field in a water shell using YASARA tools (www.yasara.org/).”</p><disp-quote content-type="editor-comment"><p>A reference to the structure is needed eg for human (Almrud, J. J., Oliveira, M. A., Kern, A. D., Grishin, N. V., Phillips, M. A., and Hackert, M. L. (2000) Crystal structure of human ornithine decarboxylase at 2.1 Å resolution: structural insights to antizyme binding. J. Mol. Biol. 295, 7-16 ) or mouse (Kern, A. D., Oliveira, M. A., Coffino, P., and Hackert, M. L. (1999) Structure of mammalian ornithine decarboxylase at 1.6 Å resolution: stereochemical implications of PLP-dependent amino acid decarboxylases. Structure 7, 567-581).</p></disp-quote><p>Please see above, Thanks.</p><disp-quote content-type="editor-comment"><p>4. A reference to the original work of the very gifted chemists and pharmacologists that lead to the conceptualization and production of DFMO would be appropriate. For example, Metcalf, B. W., Bey, P., Danzin, C., Jung, M. J., Casara, P., and Vevert, J. P. (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E. C. 4. 1. 1. 17) by substrate and product analogues. J. Am. Chem. Soc. 100, 2551-2553.</p></disp-quote><p>The reviewer makes an excellent point that the addition of a reference to recognize the research of those who worked to make treatment with DFMO possible in the first place would add great value to the manuscript. This is now ref 6 and a sentence recognizing this work and a new citation have been added. The sentence in the introduction reads as “Eflornithine is the result of work done on developing inhibitors that lead to irreversible enzymatic inactivation of ODC from nearly forty years ago.<sup>6</sup>”</p></body></sub-article></article>